The medicine, marketed by Roche Registration GmbH, is already approved in the EU for treating the inflammatory conditions rheumatoid arthritis, systemic juvenile idiopathic arthritis, juvenile idiopathic polyarthritis, giant cell arteritis and cytokine release syndrome (CRS).
EMA recommends approval for use of RoActemra in adults with severe COVID-19
-
- Site Admin
- Beiträge: 725
- Registriert: Do Mai 31, 2018 9:27 pm
EMA recommends approval for use of RoActemra in adults with severe COVID-19
https://www.ema.europa.eu/en/news/ema-recommends-approval-use-roactemra-adults-severe-covid-19